Phi implemented more than a decade ago a medical department that ensures safety use and medical information of our medicines.

We created a pharmacovigilance unit in accordance with good practices that  collects and monitors adverse events reported by health professionals related to our medicines. One of our mission is to contribute to the collection of information reported from healthcare professionals and transmit them to the national center of pharmacovigilance with whom we are in close collaboration. Also, our medical representatives are trained on PHI pharmacovigilance procedures and are aware of the importance of these reports for the safety of our medicines.

Besides that, the medical department ensures relevance and reliability of the information provided by our representatives on our drugs. Regular and updated medical trainings allow them to be commited  to medical ethics.

We invite healthcare professionals and patients to inform us about any suspected adverse event related to our medicines.

PHI Pharmacovigilance Contact

Email :

Phone : / 85 /86

Fax :

National Center of Pharmacovigilance Contact

Website :

Phone :

N° Eco : 0801.000.180

Pharmacovigilance : Adverse event report form

Fields followed by (*) are required!

Address :
Phone* :
Date :
Gender* :

Seriousness criteria :
DeathDisabilityHospitalization or prolonged hospitalizationMedically significant according to reporterLife threateningCongenital anomaly / Birth defect